Orthofix Medical Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Orthofix is a global spine and orthopedics company whose products are distributed in more than 60 countries. Comparisons are with Q1 2023, after the January 2023 SeaSpine merger; nearly all of SeaSpine’s Q1 2023 results were included.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net sales | $188.6 million | $175.2 million |
| Gross profit / margin | $127.2 million / 67.5% | $110.3 million / 63.0% |
| Operating loss | $29.3 million | $59.7 million |
| Net loss | $36.0 million; $0.95 per diluted share | $60.9 million; $1.71 per diluted share |
| Adjusted EBITDA (non-GAAP) | $7.7 million | $3.2 million |
| Cash used in operating activities | $18.6 million | $34.0 million |
| Free cash flow (non-GAAP) | $(29.4) million | $(45.9) million |
Sales increased 7.7% reported and 7.5% at constant currency. Gross margin expanded 4.5 percentage points. Management attributed part of the gross-profit improvement to $8.6 million less amortization of SeaSpine acquired-inventory fair-value step-up. Lower merger integration costs and other expense reductions also contributed to the narrower operating loss.
Global Spine sales grew 8.1% to $161.3 million: Bone Growth Therapies rose 10.0%, and Spinal Implants, Biologics and Enabling Technologies rose 7.2%. Global Orthopedics sales increased 5.1% to $27.3 million; U.S. growth was partly offset by weaker international sales.
Cash, cash equivalents and restricted cash were $29.5 million at quarter-end, including $2.5 million restricted, versus $37.8 million at December 31, 2023. Carrying-value debt was $118.2 million, up from $94.4 million at year-end; principal outstanding was $125.0 million. The company had no revolver borrowings at March 31 and reported compliance with its financing covenants. Capital expenditures were $10.8 million.
Changes, outlook and notable items
- Sales and adjusted EBITDA improved year over year, while GAAP results remained loss-making. Net cash use from operations improved by $15.4 million, but cash declined during the quarter.
- Management cited ongoing demand, distributor expansion, product adoption and U.S. commercial execution as sales drivers. Bone Growth Therapies had five consecutive quarters of double-digit sales increases. No specific full-year financial guidance is provided in the filing.
- Sales and marketing expense rose 6.7%, partly from variable compensation and instrumentation depreciation. General and administrative expense fell 35.2%, mainly due to lower merger-related costs and synergies, partly offset by $2.2 million of succession charges. R&D expense declined 16.4%, including lower EU regulatory-compliance and integration costs.
- Interest expense increased to $4.6 million from $1.3 million, principally due to higher debt. Other expense included a foreign-exchange remeasurement loss. The company drew the $25 million delayed-draw term loan in March and used proceeds to repay a $15 million revolver balance.
- Former executives have brought arbitration claims alleging wrongful termination and seeking severance, equity value and other damages. The company disputes the claims and says it cannot reasonably estimate a possible loss or range.
- The company accrued $7.7 million for Italy’s medical-device payback program; the ultimate liability may differ. A distributor has exercised a purchase option under a merger-related agreement, and negotiations are ongoing. Assuming all relevant purchase options were exercised, estimated share issuance would be approximately 1.5 million shares.
- A $9.7 million Lattus contingent-consideration liability is based on future product sales and valuation assumptions; actual payments may be higher or lower. The Neo Medical convertible loan was converted into preferred shares in April 2024, after quarter-end.
- Management reported that disclosure controls were ineffective at March 31, 2024, because a previously identified material weakness in review controls for business combinations and goodwill recoverability remained unremediated. Remediation is ongoing; management said the weakness had not resulted in financial-statement misstatements.
Key facts for investors to verify
- Whether revenue growth and improved gross margin persist as acquired-inventory step-up amortization and merger-related costs diminish.
- Cash burn, working-capital needs, debt service and continued compliance with credit-facility covenants.
- Progress and timing of remediation of the material weakness and restoration of effective disclosure controls.
- Developments in former-executive arbitrations, the Italian payback dispute and the distributor buyout negotiations, including potential cash or share dilution.
- Management’s future outlook and the extent to which adjusted EBITDA and free-cash-flow trends translate into sustainable GAAP profitability and cash generation.